Business
Kymera Therapeutics to Present New In Vivo Data Demonstrating the Broad Anti-Inflammatory Activity of its IRAK4 Degrader KT-474 at IMMUNOLOGY2021™ Annual Meeting
Data demonstrate KT-474’s superiority compared to a clinically active small molecule IRAK4 kinase inhibitor across a wide variety of immune-inflammatory
About this update from Kymera Therapeutics, Inc.
[{"type":"text","content":"Data demonstrate KT-474’s superiority compared to a clinically active small molecule IRAK4 kinase inhibitor across a wide variety of immune-inflammatory preclinical models\nWATERTOWN, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that a late-breaking abstract featuring new preclinical data for its IRAK4 degrader KT-474 has been selected for presentation at the American Association of Immunologists’ Virtual IMMUNOLOGY2021™ annual meeting, taking place from May 10 - 15, 2021. “We are excited to present new in vivo data demonstrating KT-474’s broad and potent anti-inflammatory activity in both mechanistic and disease models of inflammation,\" said Nello Mainolfi, PhD, Co-Founder, President and CEO, Kymera Therapeutics. “These data have broadened the potential clinical impact of KT-474 in diseases driven by IL-33/36, as well as Th17-driven inflammation, and continue to demonstrate superiority both in vitro and in vivo over clinically active IRAK4 kinase inhibitors.” Abstract Presentation Details: Abstract: 1307Title: IRAK4 degradation abrogates cytokine release and improves disease endpoints in murine models of IL-33/36- as well as Th17-driven inflammationSession: Novel therapeutic approaches for the modulation of autoimmune and allergic diseasesSession Time: 9:00 a.m. - 10:30 a.m. ET on Thursday, May 13, 2021Presenter: Cedric Hubeau, Ph.D. The late-breaking abstract is now available at https://www.immunology2021.org/. The poster presentation will be available for download on May 10, 2021 at https://www.kymeratx.com/scientific-resources/. About IRAK4 and KT-474IRAK4 is a key protein involved in inflammation mediated by the activation of toll-like receptors (TLRs) and IL-1 receptors (IL-1Rs). Aberrant activation of these pathways is the underlying cause of multiple immune-inflammatory conditions. KT-474, a potential first-in-class, orally bioavailable IRAK4 degrader, is being developed for the treatment of TLR/IL-1R-driven immune-inflammatory diseases with high unmet medical need, such as atopic dermatitis, hidradenitis suppurativa, rheumatoid arthritis, and potentially others. KT-474 is designed to block TLR/IL-1R-mediated inflammation more b...